ATOS - Atossa Therapeutics, Inc.
(NaN%)
We couldn't determine Recommendation based on the data we have.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Atossa Therapeutics, Inc. (ATOS) - http://www.atossatherapeutics.com
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Steven C. Quay
Employees - 6
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.